Clenbuterol vs LGD-4033
Well Studied vs Moderate Research
monitor Mechanism-based · 51% Both Clenbuterol and LGD-4033 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Clenbuterol LGD-4033
Weight 277.19 Da 338.25 Da
Half-life ~36 hours ~24-36 hours
Type Sympathomimetic amine (C12H18Cl2N2O) Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
Clenbuterol
01 Increased basal metabolic rate and thermogenesis for accelerated fat loss
02 Preferential mobilization of stored body fat through enhanced lipolysis
03 Anti-catabolic effects that help preserve lean muscle mass during caloric restriction
04 Bronchodilation and improved respiratory capacity during intense exercise
05 Appetite suppression in many users, supporting adherence to caloric deficit
06 Oral administration with no injections required
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Side Effects
Clenbuterol
Tremors and shaking (especially hands) - most pronounced in the first 3-5 days
Tachycardia (elevated heart rate, typically 10-20 bpm above baseline)
Insomnia and sleep disturbance, particularly with afternoon or evening dosing
Muscle cramps (calves, forearms, back) due to taurine depletion
Increased sweating and elevated body temperature
Headaches, particularly during dose ramp-up
Nervousness, anxiety, and restlessness
Increased blood pressure
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Pre-existing cardiovascular disease, cardiomyopathy, or arrhythmia
Uncontrolled hypertension
Hyperthyroidism or thyrotoxicosis
Hypokalemia or electrolyte imbalances
Known hypersensitivity to clenbuterol or sympathomimetic amines
Concurrent use of other stimulants (ephedrine, amphetamines) or MAO inhibitors
Pregnancy or breastfeeding
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
Clenbuterol LGD-4033
Status Well Studied Moderate Research
References 5 studies 5 studies
Latest 2021 2018
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.